StockData
Context Therapeutics Inc. logo

Context Therapeutics Inc. (CNTX) company profile

CNTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$0.17−0.01 (-8.24%)

Close on Nov 16, 2026Market cap $15.24MP/E –Yield –

About Context Therapeutics

Pharmaceutical Preparations, SIC 2834

Context Therapeutics is a clinical-stage biopharmaceutical company that advances T cell engaging bispecific antibody therapeutics for the treatment of solid tumors. Its drug development pipeline targets patient populations with unmet oncology needs, including gynecologic, testicular, bladder, lung, colon, and breast cancers. The company's lead investigational drug candidates include CTIM-76, CT-95, and CT-202, which direct immune responses against specific tumor-associated antigens such as Claudin 6, Mesothelin, and Nectin-4. Because Context Therapeutics remains in clinical development, it has not brought commercial products to market.

The company operates without internal manufacturing, sales, or commercial product distribution facilities, choosing to outsource research, drug product manufacturing, and diagnostic preparation to external contract partners. It pursues clinical trials and global patent protection across multiple jurisdictions, including the United States, Europe, Canada, Australia, and parts of Asia, while retaining worldwide development and commercialization rights to its core programs. Context Therapeutics does not identify specific physical headquarters locations or facility counts in the provided text.

Summary of the business section of Context Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Context Therapeutics Inc.
Founded
2021
Headquarters
Philadelphia, PA
Address
2001 Market Street, Suite 3915 Unit #15 19103
Phone
(267) 225-7416
Employees
15, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
CohnReznick LLP, Parsippany, New Jersey

Stock & identifiers

Ticker
CNTX
Exchange
Nasdaq
IPO date
Oct 20, 2021
Shares outstanding
92M, Aug 3, 2026
Public float
$57.90M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SEC CIK
1842952
CUSIP
21077P108
ISIN
US21077P1084
FIGI
BBG011YW6H86
Share class FIGI
BBG011YW6J46
LEI
549300U5ISIWCBXD6W77
EIN
86-3738787

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Martin A. LehrChief Executive Officer, Director1,079,891
Alex C. LevitChief Legal Officer, Corp. Sec81,983
Jennifer Lynn Minai-AzaryChief Financial Officer80,010
Karen Deborah ChaginChief Medical Officer–
Ullmann Claudio DanskyChief Medical Officer–
Andy PasternakDirector–
Linda WestDirector–
Karen L. SmithDirector–
Jennifer Evans StaceyDirector–
Philip W. KantoffDirector3,533
Luke Nathaniel WalkerDirector–

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsIncentive payOtherTotalvs. prior year
Martin Lehr
Chief Executive Officer
$588.52K$15.00K$551.42K$300.00K$10.50K$1.47M+45%
Alex Levit
Chief Legal Officer and Corporate Secretary
$397.81K$8.00K$240.36K$160.00K$10.50K$816.67K+22%
Jennifer Minai-Azary
Chief Financial Officer and Treasurer
$421.73K$8.50K$255.41K$170.00K$10.50K$866.14K+24%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Oct 20, 2021
Offer price
$5.00
Securities offered
5,000,000
Gross proceeds
$25.00M
Exchange
Nasdaq
First trading day
Oct 20, 2021
First-day close
$5.10+2.0%
Lock-up ends (est.)
Apr 18, 2022

“Per Share Total Initial public offering price $ 5.00 $ 25,000,000 Underwriting discounts and commissions (1) $ 0.375 $ 1,875,000 Proceeds, before expenses, to us $ 4.625 $ 23,125,000 (1) In addition, we have agreed to reimburse the underwriter for certain expenses.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of March 1, 2026, we had fifteen full-time employees and no part-time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?